Physician profile
Vidhya Nair
NPI 1790214997
$9,273.89
in general payments reported to CMS, 2019-2025
7 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $185 · 2022: $102 · 2023: $381 · 2024: $8,085 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,020 · Food and Beverage: $1,257 · Travel and Lodging: $1,234 · Grant: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,020.00 |
| Food and Beverage | $1,257.36 |
| Travel and Lodging | $1,233.98 |
| Grant | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,734.59 | 2024 | Trodelvy |
| Seagen INC. | $483.43 | 2022-2023 | Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $350.00 | 2024 | |
| Stemline Therapeutics INC. | $327.72 | 2025 | Orserdu |
| Incyte Corporation | $251.50 | 2020-2021 | |
| Genentech USA, INC. | $68.00 | 2025 | |
| Adc Therapeutics America, INC. | $58.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.